Brief: Timber Pharmaceuticals Receives Positive Opinion On Orphan Designation From European Medicines Agency For Tmb-001 For Treatment Of Autosomal Recessive Congenital Ichthyosis

Trex Wind-Down

14/09/2022 14:00

Sept 14 (Reuters) - Timber Pharmaceuticals Inc  TMBR.A :
    * TIMBER PHARMACEUTICALS RECEIVES POSITIVE OPINION ON ORPHAN
DESIGNATION FROM EUROPEAN MEDICINES AGENCY FOR TMB-001 FOR
TREATMENT OF AUTOSOMAL RECESSIVE CONGENITAL ICHTHYOSIS
    * TIMBER PHARMACEUTICALS INC - EUROPEAN COMMISSION EXPECTED
TO
ISSUE ITS DECISION ON ORPHAN DESIGNATION IN APPROXIMATELY 30
DAYS

Source text for Eikon:  ID:nGNX3nRv38 
Further company coverage:  TMBR.A 

 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))